Evre 1-3 Kolon Kanserinde Radyolojik Tutulumun Lokalizasyonu ve Sağ Kalıma Etkisi

Yıl 2023, Cilt: 13 Sayı: 1, 55 - 61, 16.03.2023

Özlem Özkul

https://doi.org/10.31832/smj.1210830

Öz

Amaç: Kolon kanserinin tek bir hastalık olmadığı, sağ ve sol kolon kanserinin epidemiyolojik, klinikopatolojik ve prognostik açıdan farklılıklar gösterdiği çok sayıda çalışma ile desteklenmiştir. Biz de çalışmamızda iki grup arasındaki demografik, klinik, biyokimyasal ve inflamatuar belirteçleri ve genel sağ kalım verilerini karşılaştırarak literatüre katkıda bulunmayı amaçladık.
Gereç ve Yöntemler: Çalışmaya evre 1-3 kolon kanserli rezektabl 77 hasta dâhil edildi (% 58,40 erkek, % 41,60 kadın). Hastalar sağ ve sol kolon kanseri olarak iki gruba ayrıldı. Gruplar arasında yaş, cinsiyet, evre, lenf nodu sayısı, patolojik ve biyokimyasal parametreler ile inflamatuar belirteçler karşılaştırıldı.
Bulgular: Sağ kolon kanserinde total çıkarılan lenf nodu sayısı (p: 0,010) ve mikrosatellit instabilite (MSI) yüksek hasta sayısı (p:0,001) sol kolon kanserine göre anlamlı olarak daha yüksek bulundu. Sol kolon kanserinde ise nötrofil sayısı sağ kolon kanserine göre daha fazlaydı (p: 0,008).
Sonuç: Sağ kolon kanserinde MSI yüksek hasta sayısı sola göre daha fazlaydı. Total çıkarılan lenf nodu sayısı da sağ kolon kanserinde daha yüksekti. Bunun aksine nötrofil sayısı sol kolon kanserinde daha yüksek bulundu. Sağ kalım analizleri için daha uzun takip süresine ihtiyaç vardı.

Anahtar Kelimeler

Evre, Kolon kanseri, mGPS, MSI, Sağ kalım

Kaynakça

• 1. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet. 2016;388(10053):1459-544.
• 2. Benson AB, 3rd, Venook AP, Cederquist L, Chan E, Chen YJ, Cooper HS, et al. Colon Cancer, Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2017;15(3):370-98.
• 3. Bufill JA. Colorectal cancer: evidence for distinct genetic categories based on proximal or distal tumor location. Ann Intern Med. 1990;113(10):779-88.
• 4. Mik M, Berut M, Dziki L, Trzcinski R, Dziki A. Right- and left-sided colon cancer - clinical and pathological differences of the disease entity in one organ. Arch Med Sci. 2017;13(1):157-62.
• 5. Benedix F, Kube R, Meyer F, Schmidt U, Gastinger I, Lippert H. Comparison of 17,641 patients with right- and left-sided colon cancer: differences in epidemiology, perioperative course, histology, and survival. Dis Colon Rectum. 2010;53(1):57-64.
• 6. Powell AGMT, Wallace R, McKee RF, Anderson JH, Going JJ, Edwards J, et al. The relationship between tumour site, clinicopathological characteristics and cancer-specific survival in patients undergoing surgery for colorectal cancer. Colorectal Disease. 2012;14(12):1493-9.
• 7. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487(7407):330-7.
• 8. Gao R, Kong C, Huang L, Li H, Qu X, Liu Z, et al. Mucosa-associated microbiota signature in colorectal cancer. Eur J Clin Microbiol Infect Dis. 2017;36(11):2073-83.
• 9. Dejea CM, Wick EC, Hechenbleikner EM, White JR, Mark Welch JL, Rossetti BJ, et al. Microbiota organization is a distinct feature of proximal colorectal cancers. Proc Natl Acad Sci U S A. 2014;111(51):18321-6.
• 10. Bustamante-Lopez LA, Nahas SC, Nahas CSR, Pinto RA, Marques CFS, Cecconello I. IS THERE A DIFFERENCE BETWEEN RIGHT- VERSUS LEFT-SIDED COLON CANCERS? DOES SIDE MAKE ANY DIFFERENCE IN LONG-TERM FOLLOW-UP? Arq Bras Cir Dig. 2019;32(4):e1479.
• 11. Meguid RA, Slidell MB, Wolfgang CL, Chang DC, Ahuja N. Is there a difference in survival between right- versus left-sided colon cancers? Ann Surg Oncol. 2008;15(9):2388-94.
• 12. Weiss JM, Pfau PR, O'Connor ES, King J, LoConte N, Kennedy G, et al. Mortality by stage for right- versus left-sided colon cancer: analysis of surveillance, epidemiology, and end results--Medicare data. J Clin Oncol. 2011;29(33):4401-9.
• 13. Jess P, Hansen IO, Gamborg M, Jess T. A nationwide Danish cohort study challenging the categorisation into right-sided and left-sided colon cancer. BMJ Open. 2013;3(5).
• 14. Saltzstein SL, Behling CA. Age and time as factors in the left-to-right shift of the subsite of colorectal adenocarcinoma: a study of 213,383 cases from the California Cancer Registry. J Clin Gastroenterol. 2007;41(2):173-7.
• 15. Gao P, Song YX, Xu YY, Sun Z, Sun JX, Xu HM, et al. Does the prognosis of colorectal mucinous carcinoma depend upon the primary tumour site? Results from two independent databases. Histopathology. 2013;63(5):603-15.
• 16. Hansen IO, Jess P. Possible better long-term survival in left versus right-sided colon cancer - a systematic review. Dan Med J. 2012;59(6):A4444.
• 17. Wray CM, Ziogas A, Hinojosa MW, Le H, Stamos MJ, Zell JA. Tumor subsite location within the colon is prognostic for survival after colon cancer diagnosis. Dis Colon Rectum. 2009;52(8):1359-66.
• 18. Warschkow R, Sulz MC, Marti L, Tarantino I, Schmied BM, Cerny T, et al. Better survival in right-sided versus left-sided stage I - III colon cancer patients. BMC Cancer. 2016;16:554.
• 19. Iacopetta B. Are there two sides to colorectal cancer? Int J Cancer. 2002;101(5):403-8.
• 20. Kwak HD, Ju JK, Lee SY, Kim CH, Kim YJ, Kim HR. Comparison of Right-side and Left-side Colon Cancers Following Laparoscopic Radical Lymphadenectomy. J Invest Surg. 2021;34(2):142-7.
• 21. Turner MC, Becerra D, Sun Z, Watson J, Leung K, Migaly J, et al. The side of the primary tumor affects overall survival in colon adenocarcinoma: an analysis of the national cancer database. Tech Coloproctol. 2019;23(6):537-44.
• 22. Yang CY, Yen MH, Kiu KT, Chen YT, Chang TC. Outcomes of right-sided and left-sided colon cancer after curative resection. Sci Rep. 2022;12(1):11323.
• 23. Qiu MZ, Pan WT, Lin JZ, Wang ZX, Pan ZZ, Wang FH, et al. Comparison of survival between right-sided and left-sided colon cancer in different situations. Cancer Med. 2018;7(4):1141-50.
• 24. Pheby DF, Levine DF, Pitcher RW, Shepherd NA. Lymph node harvests directly influence the staging of colorectal cancer: evidence from a regional audit. J Clin Pathol. 2004;57(1):43-7.
• 25. Ratto C, Sofo L, Ippoliti M, Merico M, Bossola M, Vecchio FM, et al. Accurate lymph-node detection in colorectal specimens resected for cancer is of prognostic significance. Dis Colon Rectum. 1999;42(2):143-54; discussion 54-8.
• 26. Hutchins G, Southward K, Handley K, Magill L, Beaumont C, Stahlschmidt J, et al. Value of mismatch repair, KRAS, and BRAF mutations in predicting recurrence and benefits from chemotherapy in colorectal cancer. J Clin Oncol. 2011;29(10):1261-70.
• 27. Gervaz P, Bucher P, Morel P. Two colons-two cancers: paradigm shift and clinical implications. J Surg Oncol. 2004;88(4):261-6.
• 28. Sargent DJ, Marsoni S, Monges G, Thibodeau SN, Labianca R, Hamilton SR, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol. 2010;28(20):3219-26.
• 29. Sinicrope FA, Mahoney MR, Smyrk TC, Thibodeau SN, Warren RS, Bertagnolli MM, et al. Prognostic impact of deficient DNA mismatch repair in patients with stage III colon cancer from a randomized trial of FOLFOX-based adjuvant chemotherapy. J Clin Oncol. 2013;31(29):3664-72.
• 30. Ribic CM, Sargent DJ, Moore MJ, Thibodeau SN, French AJ, Goldberg RM, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med. 2003;349(3):247-57.
• 31. Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol. 2010;28(3):466-74.
• 32. Hayama T, Ozawa T, Asako K, Kondo R, Ono K, Okada Y, et al. Impact of Colon Cancer Location on the Prognostic Significance of Nutritional Indexes and Inflammatory Markers. In Vivo. 2021;35(2):1261-9.
• 33. Guo D, Li X, Xie A, Cao Q, Zhang J, Zhang F, et al. Differences in oncological outcomes and inflammatory biomarkers between right-sided and left-sided stage I-III colorectal adenocarcinoma. Journal of Clinical Laboratory Analysis. 2020;34(4):e23132.
• 34. McMillan DC, Crozier JE, Canna K, Angerson WJ, McArdle CS. Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer. Int J Colorectal Dis. 2007;22(8):881-6.